Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF: Opposing effects observed with different cytotoxic drugs and time exposure

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 931-938

  Ciaiolo, Carlo ^a   Ferrero, Dario ^a   Pugliese, Agostino ^b   Ortolano, Barbara ^a   Borrione, Paolo ^a   Pileri, Alessandro ^a  

^a Osp M   (Italy)

^b Divisione di Cardiologia   (Italy)

Author keywords

Acute myeloid leukemia; Cytosine arabinoside; GM CSF; Methotrexate

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL DEATH; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; METHOTREXATE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032846455     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00111-3     Document Type: Article

References (37)

1. De Vita V.T. Cell kinetics and the chemotherapy of cancer. Cancer Chemoter. Rep. 2:1971;23.
2. Chabner B.A., Myers C.E., Coleman C.N. The clinical pharmacology of antineoplastic agents. N. Engl. J. Med. 292:1975;1159.
3. Clarkson B., Fried J., Strife A. Studies of cellular proliferation in human leukemia. Cancer. 25:1970;1237.
4. Gavosto F. Kinetic conditions preventing the eradication of human leukemia. Eur. J. Cancer. 13:1977;407.
5. Gabutti V., Pileri A., Tarocco R.P., Gavosto F., Cooper E.H. Proliferative potential of out of cycle leukemic cells. Nature. 224:1969;375.
6. Burke P.J., Owens A.H. Attempted recruitment of leukemic myeloblasts to proliferative activity by sequential drug treatment. Cancer. 28:1971;830.
7. Burke P.J., Vaughan W.P., Karp J.E. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood. 55:1980;960.
8. Klein H.O., Lennartz K.J. Chemotherapy after syncronization of tumor cells. Semin. Hematol. 11:1974;203.
9. Zittoun R.A., Mandelli F., Willemze R., De Witte T., Labar B., Resegotti L. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 23:1995;332.
10. International Bone marrow Transplantation Registry Transplant or chemotherapy in acute myelogenous leukemia. Lancet. 1:1989;1119.
11. Robinson BE, Quesenberry PJ. Hematopoietic growth factors: overview and clinical applications. Parts I, II and III. Am. J. Med. Sci. 1990;300:163,237,311.
12. Anderson J.R., Anderson P.N., Armitage J.O., Beckhardt S., Bennett C.L., Bodey G.P. et al. American Society of Clinical Oncology recomendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J. Clin. Oncol. 12:1994;2471.
13. Ciaiolo C., Ferrero D., Pugliese A., Biglino A., Marletto G., Tonello M. et al. Enhancement of methotrexate cytotoxicity by modulation of proliferative activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line. Tumori. 74:1988;537.
14. Lista P., Porcu, Avanzi G.C., Pegoraro L. Interleukin 3 enhances the cytotoxic activity of 1-(-d-arabinofuranosylcytosine (Ara-C) on acute myeloblastic leukemia (AML) cells. Br. J. Haematol. 70:1988;121.
15. Cannistra S.A., Groshek P., Griffin J.D. Granulocyte-macrophage colony stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 3:1989;328.
16. Butturini A., Santucci M.A., Gale R.P., Perocco P., Tura S. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cell in vitro: a model for leukemia chemotherapy. Leuk. Res. 14:1990;743.
17. Andreeff M., Tafuri A., Hegewisch-Becker S. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Haematol. Blood Trans. 33:1990;747.
18. Boekhorst P.A., Lowenberg B., Vlastuin M., Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 7:1993;1191.
19. Powell B.L., Wang L.M., Gregory B.W., Case L.D., Kucera G.L. GM-CSF and asparaginase potentiate Ara-C cytotoxicity in HL-60 cells. Leukemia. 11:1995;405.
20. Tafuri A., Lemoli R.M., Chen R., Gulati S.C., Clarkson B.D., Andreeff M. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia. 8:1994;749.
21. Van der Lely N., De Witte T., Wessels J., Raymakers R., Muus P., Preijers F. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann. Hematol. 68:1994;225.
22. Vaillard J.F., Grosset C., Lacombe F., David S., Mahon F.X., Barbot C., Vianes I., Dupouy M., Reiffers J. Effect of stem cell factor on leukemic progenitor cell growth and sensitivity to cytosine-arabinoside. Leuk. Res. 20:1996;915.
23. Cannistra S.A., Di Carlo J., Groshek P., Kanakura Y., Berg D., Mayer R.J., Griffin J.D. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 5:1991;230.
24. Estey E.H., Dixon D., Kantarjian H.M., Keating M.J., McCredie K., Bodey G.P. et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 75:1990;1766.
25. Estey E.H., Thall P.F., Kantarjian H.M., O'Brien S., Koller C.A., Beran M. et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C+daunorubicin: comparison to patients treated without GM-CSF. Blood. 79:1992;2246.
26. Bettelheim P., Valent P., Andreeff M., Tafuri A., Haimi J., Gorischek C. et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood. 77:1991;700.
27. Kohseisho Leukemia Study Group , Ohno R., Naoe T., Kanamaru A., Yoshida M., Hiraoka A., Kobayashi T. et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood. 83:1994;2086.
28. Estey E.H., Thall P., Andreeff M., Beran M., Kantarjian H., O'Brien S. et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12:1994;671.
29. Sundman-Engberg B., Tidefelt U., Paul C. Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. Eur. J Haematol. 56:1996;1.
30. Jolivet J., Cowan K.H., Curt G.A., Clenendinn N.J., Chabner B.A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309:1983;1094.
31. Ho D.H.W., Frei E. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clin. Pharmacol. Ther. 12:1971;944.
32. Lange B., Valtieri M., Santoli D., Caracciolo D., Mavilio F., Gemperlein I. et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 70:1987;192.
33. Taswell C. Limiting dilution assay for the determination of immunocompetent cell frequency. J. Immunol. 126:1981;1614.
34. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271.
35. Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy. Blood. 80:1989;1750.
36. Koistinen P., Wang C., Curtis J.E., McCulloch E.A. Granulocyte-macrophage colony-stimulating factor and interleukin 3 protect leukemic blast cells from Ara-C toxicity. Leukemia. 5:1991;789.
37. Gore S.D., Burke P.J., Weng L.J. Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia. Leuk. Lymphoma. 29:1998;339.